Active, not recruitingPhase 1NCT06764771
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
Studying MiT family translocation renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bristol-Myers Squibb
- Principal Investigator
- Bristol-Myers SquibbBristol-Myers Squibb
- Intervention
- BMS-986488(drug)
- Enrollment
- 437 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2027
Study locations (7)
- Local Institution - 0021, Hackensack, New Jersey, United States
- Local Institution - 0020, Allentown, Pennsylvania, United States
- Local Institution - 0024, Germantown, Tennessee, United States
- Local Institution - 0031, Brisbane, Queensland, Australia
- Local Institution - 0032, Vancouver, British Columbia, Canada
- Local Institution - 0015, Montreal, Quebec, Canada
- Local Institution - 0016, Québec, Quebec, Canada
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06764771 on ClinicalTrials.govOther trials for MiT family translocation renal cell carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07571551Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell CarcinomaJinling Hospital, China
- RECRUITINGNANCT07073703Effectiveness of a Personalized 6-month Programme on Frailty in Older Patients Treated for Bladder or Kidney Cancer.Centre Hospitalier Universitaire de Saint Etienne
- RECRUITINGNANCT06138067Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer PatientsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- RECRUITINGPHASE1NCT06966024Study of DCC-2812 in Participants With Advanced Genitourinary CancersDeciphera Pharmaceuticals, LLC
- RECRUITINGPHASE2NCT07087860Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder CancersMayo Clinic
- RECRUITINGPHASE2NCT07018622Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy ToxicityInstituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- ACTIVE NOT RECRUITINGNCT06917560Serological Autoantibodies in Early Kidney Cancer Diagnosis and Prognosis: A Multicenter StudyFirst Affiliated Hospital of Fujian Medical University
- RECRUITINGNCT07166445Deep Learning for Automated Discrimination Between Stage T1-T2 and T3 Renal Cell Carcinoma on Contrast-Enhanced CTPeking University First Hospital
See all trials for MiT family translocation renal cell carcinoma →